Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis
- 20 September 2018
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (2) , e54-e58
Abstract
Acute myeloid leukemia represents a heterogeneous group of disorders characterized by the rapid expansion of immature myeloid cells (blasts) in the bone marrow. There is wide disease heterogeneity and patient risk-stratification principally relies on cytogenetic-molecular data. Bone-marrow mesenchymal stem/stromal cells are key components of the hematopoietic niche thought to contribute to leukemia pathogenesis. We recently reported a correlation between behaviors of bone-marrow mesenchymal stem/stromal cells from acute myeloid leukemia patients in vitro and overall survival. To elaborate on this finding, we investigated the capacity of bone-marrow mesenchymal stem/stromal cells from risk-stratified de novo acute myeloid leukemia patients to regulate the homeostasis of healthy CD34+ hematopoietic stem/progenitor cells, and to exert anti-inflammatory effects in vivo in a pre-clinical model of severe acute colitis. We report that regardless of risk-group, bone-marrow mesenchymal stem/stromal cells from acute myeloid leukemia patients support, similar to those derived from healthy bone-marrow the survival, proliferation, differentiation and clonogenecity of CD34+ cells in vitro, and the in vivo immune deficient mice repopulating assays. Additionally, bone-marrow mesenchymal stem/stromal cells from acute myeloid leukemia patients were capable of reversing the inflammatory phenotype in preclinical models of acute severe colitis, showing a greater anti-inflammatory capacity compared to those derived from healthy bone marrow. Collectively, bone-marrow mesenchymal stem/stromal cells from acute myeloid leukemia patients retain the capacity to support healthy hematopoietic stem/progenitor cells and can suppress inflammation in vivo.Keywords
This publication has 15 references indexed in Scilit:
- Distinct roles of mesenchymal stem and progenitor cells during the development of acute myeloid leukemia in miceBlood Advances, 2018
- Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment OutcomesStem Cell Reports, 2017
- Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular MechanismsFrontiers in Immunology, 2017
- Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel diseaseExperimental & Molecular Medicine, 2017
- Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia CellsStem Cells, 2015
- Human Bone Marrow Stromal Cells Lose Immunosuppressive and Anti-inflammatory Properties upon Oncogenic TransformationStem Cell Reports, 2014
- Acute Myelogenous Leukemia-Induced Sympathetic Neuropathy Promotes Malignancy in an Altered Hematopoietic Stem Cell NicheCell Stem Cell, 2014
- Self-Renewing Human Bone Marrow Mesenspheres Promote Hematopoietic Stem Cell ExpansionCell Reports, 2013
- Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsisGut, 2009
- Mesenchymal stem cells and their use as cell replacement therapy and disease modelling toolJournal of Cellular and Molecular Medicine, 2008